What is BVS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.26B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BVS?

P/E (TTM) is 23.10 and 52-week range is $6.47 to $15.89 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BVS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BVS?

The company profile lists revenue (TTM) near $691M, net income (TTM) near $65M, EPS (TTM) near $0.78 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Bioventus Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Durham, North Carolina, US, 84.1M shares outstanding, ISIN US09075A1088 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Bioventus Inc

$BVS

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 930 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

Employees

940

Website

www.bioventus.com/

IPO

2021-02-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)